Search

Sibeprenlimab

[A274848, A274853, A274858] Elevated APRIL levels are often observed in inflammatory disorders, including immunoglobulin A nephropathy (IgAN). … Sibeprenlimab is a Proliferation Inducing Ligand (APRIL) blocker.[L54633] APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells.

Primaquine

An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. … It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria.

Acitretin

An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.

Benznidazole

[L939] It is the first treatment made available in the United States for Chagas disease. … Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.

Ox bile extract

Givinostat

Givinostat is a small molecule histone deacetylase (HDAC) inhibitor. … It has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lymphoma, as well as several muscular dystrophies

rdESAT-6

rdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]

Darvadstrocel

Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms. … [L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication.

mRNA-1283

[L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

Gestrinone

Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America. … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and